Refine by
Device Therapy Articles & Analysis
174 news found
CD Formulation, a reputable contract research organization (CRO) based in New York, has become a trusted partner for many pharmaceutical companies around the world seeking innovative drug formulation methods and solutions. Recently, CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the development of cutting-edge CAR-T and CAR-NK cells for ...
The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. ...
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications ...
The ABLE Exoskeleton is a medical device designed to facilitate the work of different therapists to perform gait assistance. ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh. This achievement follows a recent on-site inspection as part of the CAP’s Laboratory Accreditation Program. ...
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which demonstrated an ORR of 16.7% in the 45 mg ...
The first implementation of a complete treatment workflow at the Helsinki University Hospital was achieved using Cosylab's OncologyOne software, the only solution on the market that covers all the needs of a radiation therapy device. OncologyOne brings to the nuBeam® system a software solution for radiation therapy that is much more readily ...
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery ...
XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan Antengene plans to submit for national health insurance reimbursement in Taiwan for XPOVIO® in Q4 2022 Shanghai and Hong Kong, PRC, October 21, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company ...
Through public-private funding initiatives, the MLSC supports innovation, research and development, commercialization, and manufacturing activities in the fields of biopharma, medical device, diagnostics, and digital health. Since its creation in 2007, the MLSC has strategically deployed more than $796 million in Massachusetts, through a combination of grants, loans, capital ...
Myrtelle Inc., (Myrtelle), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials ...
Anuncia Medical, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the ReFlow® System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid (CSF) disorders that require shunting. Anuncia Medical announced FDA clearance of ReFlow® System Mini for the treatment of cerebrospinal fluid (CSF) disorders. The FDA 510(k) clearance allows ...
It breaks through the previous limitations and is the first device that can treat the depth of SMAS in a non-invasive way. Today, Bvlaser medical beauty machinery for everyone to popularize the relevant knowledge and common problems of HIFU ultrasound machine. ...
ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors. ...
The clinical trials conducted by La Rioja’s healthcare service demonstrates the effectiveness of the only therapeutic massage robotic device that uses pressurized air to treat back pain. ...
The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed for closed surgical incision applications. The single-use, disposable NPSIMS is easily activated and operates silently during therapy delivery. A patented ...
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) ...
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced an appointment to its executive team to lead the Company’s business development efforts. Kenneth R. LaMontagne, Ph.D., joins the company as Senior ...
– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. ...
In an exciting report by ZDF, it is shown how CUREO can be used as a therapy method for Long Covid patients. In addition to acutely affected covid patients, many people struggle with the long-term consequences of the disease. These can be treated efficiently with CUREO. In addition to acutely affected Covid patients, many people also have to struggle with the long-term consequences of the virus. ...